Corresponding author: A J Brink (brinka@ampath.co.za)Background. Inappropriate use of antibiotics for non-severe upper respiratory tract infections (URTIs), most of which are viral, signifi cantly adds to the burden of antibiotic resistance. Since the introduction of pneumococcal conjugate vaccines in South Africa in 2009, the relative frequency of the major bacterial pathogens causing acute otitis media (AOM) and acute bacterial rhinosinusitis (ABRS) has changed. Recommendations. Since URTIs are mostly viral in aetiology and bacterial AOM and ABRS frequently resolve spontaneously, these recommendations include diagnostic criteria to assist in separating viral from bacterial causes and hence select those patients who do not require antibiotics. Penicillin remains the drug of choice for tonsillopharyngitis and amoxicillin the drug of choice for both AOM and ABRS. A dose of 90 mg/kg/d is recommended for children, which should be effective for pneumococci with high-level penicillin resistance and will also cover most infections with Haemophilus influenzae. Amoxicillin-clavulanate (in high-dose amoxicillin formulations available for both children and adults) should be considered the initial treatment of choice in patients with recent antibiotic therapy with amoxicillin (previous 30 days) and with resistant H. influenzae infections pending the results of studies of local epidemiology (β-lactamase production ≥15%). The macrolide/azalide class of antibiotics is not recommended routinely for URTIs and is reserved for β-lactam-allergic patients. Conclusion. These recommendations should facilitate rational anti biotic prescribing for URTIs as a component of antibiotic stewardship. They will require updating when new information becomes available, particularly from randomised controlled trials and surveillance studies of local aetiology and antibiotic susceptibility patterns.
To analyse the accuracy of the conversion formulae for estimation of glycohaemoglobin (GHb) measured by different methods, we analysed 210 samples for HbA1c using HPLC. Fifty of these specimens were analysed by micro-column chromatography (MC), 43 by electrophoresis (EP), 50 by IMX system (Abbott Laboratories), 38 by Primus HPLC and 29 by Diamat HPLC. Regression analyses were performed and the equations were used to estimate HbA1c values (HbA1c calc) for the five methods. The 95% limits of agreement between HPLC and the converted results were -1.77 to 1.71%, -1.54 to 1.54%, -0.92 to 0.88%, -0.46 to 0.56%, and -0.39 to 0.41% for MC, EP, IMX, Primus and Diamat equations, respectively. The mean relative errors were 3.4 (-28.2 to 35%), 1.3 (-22.9 to 25.5%), 0.4 (-14.6 to 15.0%), 0.51 (-6.55 to 7.57%), -0.20 (-5.8 to 5.4%), for MC, EP, IMX, Primus and Diamat, respectively. These results show that conversion formulae based on methods that do not measure HbA1c (MC, EP and IMX) are inaccurate and can mask a clinically relevant variation of HbA1c. However, GHb results obtained by HPLC methods could be interchangeably converted with an absolute variation of less than 1%. Converted HbA1c results from non-standardized methods should be interpreted with caution.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.